Literature DB >> 17725585

Superficial keratectomy and topical mitomycin C as therapy for a corneal squamous cell carcinoma in a dog.

K Karasawa1, H Matsuda, A Tanaka.   

Abstract

A 10-year-old female West Highland white terrier was presented with refractory hyperplastic keratitis of the left cornea of one month's duration. At this time, a vascularised and rough lesion 5 mm in diameter was observed on the left cornea. No other abnormality was recognised on the affected eye. The corneal neoplasm was surgically removed and histologically diagnosed as a squamous cell carcinoma. For two months after the surgery, 0.04 percent mitomycin C (MMC) eye drops were applied as adjuvant chemotherapy. Primary corneal squamous cell carcinoma with no history of keratoconjunctivitis sicca is rare in dogs. In the present report, surgical removal of the neoplasm was combined with the topical administration of the anticancer drug mitomycin C and a good prognosis was obtained. The result indicates that the combination treatment used in this case may be an appropriate therapeutic choice for corneal squamous cell carcinoma in dogs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725585     DOI: 10.1111/j.1748-5827.2007.00402.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  3 in total

1.  Mitomycin C: a promising agent for the treatment of canine corneal scarring.

Authors:  Rangan Gupta; Benjamin W Yarnall; Elizabeth A Giuliano; Jagat R Kanwar; Dylan G Buss; Rajiv R Mohan
Journal:  Vet Ophthalmol       Date:  2011-04-18       Impact factor: 1.644

2.  Topical chemotherapy with mitomycin C in a feline corneal squamous cell carcinoma.

Authors:  Esmeralda Costa Delgado
Journal:  JFMS Open Rep       Date:  2020-05-27

3.  Highly invasive and poorly differentiated corneal squamous cell carcinoma in a dog.

Authors:  López-Murcia María Del Mar; Mayordomo-Febrer Aloma; Viana David; Mozos Elena; Ortega Joaquín
Journal:  BMC Vet Res       Date:  2019-02-07       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.